Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Harald Stenmark<br>Acting Inst. Head
Harald Stenmark
Acting Inst. Head

Scientific production - Institute for Cancer Research

 PublicationsDoctoral theses
 2016 so far 

Annual report 2015 (pdf format)


Latest news

Novel cancer immunotherapy published in Cancer Research, with cover illustration

Dec. 1 issue of Cancer Research. <br>First author Kristina Berg Lorvik and senior author Alexandre Corthay
Dec. 1 issue of Cancer Research.
First author Kristina Berg Lorvik and senior author Alexandre Corthay

Collaborative efforts by researchers at the Department of Immunology and the Department of Pathology revealed the unexpected potential of tumor-specific Th2 cells for cancer immunotherapy by adoptive cell transfer (ACT) in mice.
The study was published in the December 1st 2016 issue of Cancer Research, the flagship journal of the American Association for Cancer Research. An immunofluorescence microscopy image from the paper was selected to illustrate the journal cover.


Jorrit Enserink and Tor Erik Rusten new group leaders at MCB

Enserink (left) and Rusten
Enserink (left) and Rusten

Two skilful and talented scientists have recently been appointed group leaders at the Department of Molecular Cell Biology at the Institute for Cancer Research.
Jorrit Enserink (left) heads the "Dynamic responses to cell stress" group. He was previously affiliated to the Department of Microbiology at the Division of Laboratory Medicine, OUS.
Tor Erik Rusten is heading the "Tumor-Host Biology" group, and has been promoted from his previous project group leader status at the same department.


Ceremony Friday November 18th

Ragnar Mørk legacy prize 2016 to Therese Sørlie

Therese Sørlie and Harald Stenmark
Therese Sørlie and Harald Stenmark

The 2016 "Dr. Ragnar Mørk's legacy prize" went to Therese Sørlie, head of the "Breast tumor initiation and progression group" at the Department of Cancer Genetics. This award of NOK 200.000 is annually given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research. The ceremony took  place on Friday November 18th in the Research Building at Montebello.
Therese Sørlie gave a lecture about the research activities that has earned her the award.


Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2016

Award winners during the ceremony
Award winners during the ceremony

In order to stimulate excellent research and draw attention to the hospital's extensive research activity, Oslo University Hospital reward outstanding publications regularly.

Six research groups were awarded for their excellent papers published during the first half-year of 2016 during a ceremony November 18th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.


Monday, November 21st, 2016, at 14:30 – 16:10

Oslo University Hospital research seminar: Exercise and Brain Energy


Welcome to the next Oslo University Hospital (OUH) research seminar entitled "Exercise and Brain Energy".
Time: Monday, November 21st, 2016, at 14:30 – 16:10
Place: Green Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.

Speakers: Linda Hildegard Bergersen, Cecilie Morland, Krister Andresson, Lauritz H. Kennedy, Mahdi Olive Hasan, Johanne Egge Ringholm


First-in-man trial using the PCI technology published in Lancet Oncology

Kristian Berg
Kristian Berg

Kristian Berg, the founder of the intracellular drug delivery technology photochemical internalisation (PCI) recently co-authored a paper that were published in Lancet Oncology (journal impact factor 24.69) together with collaborators at the University College London (UCL) Hospitals, London where the study was conducted and PCI Biotech.
The article "Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial" was also commented in the same issue of Lancet Oncology.